In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Anti-TIGITs Prove Their Value in 2023?

Executive Summary

The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline. 

You may also be interested in...



Ups And Downs Of Anti-TIGIT Development

Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.

Israeli Biopharma Leaders Focus On Near-Term Targets

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.

Merck & Co. Remains 'Very Confident' In TIGIT

Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV146785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel